Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches

被引:20
|
作者
van Ravesteyn, Nicolien T. [1 ]
van den Broek, Jeroen J. [1 ]
Li, Xiaoxue [2 ,3 ]
Weedon-Fekjaer, Harald [4 ]
Schechter, Clyde B. [5 ,6 ]
Alagoz, Oguzhan [7 ]
Huang, Xuelin [8 ]
Weaver, Donald L. [9 ]
Burnside, Elizabeth S. [10 ]
Punglia, Rinaa S. [11 ,12 ]
de Koning, Harry J. [1 ]
Lee, Sandra J. [2 ,3 ,12 ]
机构
[1] Erasmus MC, Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands
[2] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
[3] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA
[4] Oslo Univ Hosp, Ctr Biostat & Epidemiol, Res Support Serv, Oslo, Norway
[5] Albert Einstein Coll Med, Dept Family & Social Med, Bronx, NY 10467 USA
[6] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA
[7] Univ Wisconsin, Dept Ind & Syst Engn, Madison, WI USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[9] Univ Vermont, Dept Pathol & Lab Med, Burlington, VT USA
[10] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53706 USA
[11] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[12] Harvard Med Sch, Boston, MA USA
关键词
breast cancer epidemiology; Cancer simulation; ductal carcinoma in situ; simulation models; BREAST-CANCER; NATURAL-HISTORY; OVERDIAGNOSIS; TRENDS; WOMEN; RISK; OVERTREATMENT; RECURRENCE; DIAGNOSIS; SCIENCE;
D O I
10.1177/0272989X17729358
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background. Ductal carcinoma in situ (DCIS) can be a precursor to invasive breast cancer. Since the advent of screening mammography in the 1980's, the incidence of DCIS has increased dramatically. The value of screen detection and treatment of DCIS, however, is a matter of controversy, as it is unclear the extent to which detection and treatment of DCIS prevents invasive disease and reduces breast cancer mortality. The aim of this paper is to provide an overview of existing Cancer Intervention and Surveillance Modelling Network (CISNET) modeling approaches for the natural history of DCIS, and to compare these to other modeling approaches reported in the literature. Design. Five of the 6 CISNET models currently include DCIS. Most models assume that some, but not all, lesions progress to invasive cancer. The natural history of DCIS cannot be directly observed and the CISNET models differ in their assumptions and in the data sources used to estimate the DCIS model parameters. Results. These model differences translate into variation in outcomes, such as the amount of overdiagnosis of DCIS, with estimates ranging from 34% to 72% for biennial screening from ages 50 to 74 y. The other models described in the literature also report a large range in outcomes, with progression rates varying from 20% to 91%. Limitations. DCIS grade was not yet included in the CISNET models. Conclusion. In the future, DCIS data by grade from active surveillance trials, the development of predictive markers of progression probability, and evidence from other screening modalities, such as tomosynthesis, may be used to inform and improve the models' representation of DCIS, and might lead to convergence of the model estimates. Until then, the CISNET model results consistently show a considerable amount of overdiagnosis of DCIS, supporting the safety and value of observational trials for low-risk DCIS.
引用
收藏
页码:126S / 139S
页数:14
相关论文
共 50 条
  • [21] The significance of multifocality in ductal carcinoma in situ (DCIS)
    Spayne, J
    Nofech-Moses, S
    Hanna, W
    Pignol, JP
    Rakovitch, E
    RADIOTHERAPY AND ONCOLOGY, 2005, 76 : S2 - S3
  • [22] Ductal carcinoma in situ (DCIS): are we overtreating it?
    JM Dixon
    Breast Cancer Research, 6 (Suppl 1)
  • [23] Are We Overtreating Ductal Carcinoma In Situ (DCIS)?
    Khan, Sadia
    Epstein, Melinda
    Lagios, Michael
    Silverstein, Melvin
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : 6 - 7
  • [24] A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland
    Christine Schulze-Garg
    Jürgen Löhler
    Andreas Gocht
    Wolfgang Deppert
    Oncogene, 2000, 19 : 1028 - 1037
  • [25] Metformin for the treatment of ductal carcinoma in situ (DCIS)
    Dasgupta, Atreyi
    Edwards, David G.
    Kittrell, Frances S.
    Hilsenbeck, Susan G.
    Medina, Daniel
    Jiralerspong, Sao
    CANCER RESEARCH, 2015, 75
  • [26] Ductal carcinoma in situ (DCIS) of the male breast
    Nikolaidou, Anastasia
    Katsamakas, Michael
    Tsalikidis, Christos
    Pazarli, Elisavet
    Kriaka, Athena
    VIRCHOWS ARCHIV, 2007, 451 (02) : 205 - 205
  • [27] Survival after ductal carcinoma in situ (DCIS)
    Wahedna, Y
    Sibbering, DM
    Pinder, SE
    Ellis, IO
    Blamey, RW
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S118 - S118
  • [28] An evaluation of micrometastasis in ductal carcinoma in situ (DCIS).
    Fink, SC
    Villella, R
    Young, S
    Santoro, E
    Lara, JF
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 250 - 250
  • [29] Ductal carcinoma - In-situ (DCIS) of the breast
    McCormick, B
    Solin, LJ
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (02): : 133 - 133
  • [30] Histopathology of Ductal Carcinoma in Situ (DCIS) of the Breast
    Acs, Geza
    CURRENT CANCER THERAPY REVIEWS, 2012, 8 (03) : 162 - 171